CONCORD Q1 FY27 results at a glance
Concord Drugs Limited Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹20.94 cr |
|---|
| Revenue YoY | +53.9% |
|---|
| Operating profit | ₹1.94 cr |
|---|
| Operating margin | 9.3% |
|---|
| Net profit | ₹1.11 cr |
|---|
| Net profit YoY | +846.5% |
|---|
| Net profit QoQ | +111.0% |
|---|
| Net margin | 5.3% |
|---|
| Basic EPS | ₹0.85 |
|---|
| TTM revenue | ₹86.07 cr |
|---|
| TTM net profit | ₹2.05 cr |
|---|
| TTM net margin | 2.4% |
|---|
CONCORD Q1 FY27 results: what the numbers say
Concord Drugs Limited (CONCORD) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹20.94 cr and a net profit of ₹1.11 cr, translating into earnings per share of ₹0.85.
Compared with the same quarter a year earlier, revenue grew sharply by +53.9% and net profit grew sharply by +846.5%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹1.94 cr, an operating margin of 9.3% versus 4.8% a year ago — a gain of 4.5 percentage points.
CONCORD quarter-wise results table
Revenue
₹20.94 cr
+53.9% YoY
Net profit
₹1.11 cr
+846.5% YoY
Operating profit
₹1.94 cr
+199.3% YoY
Concord Drugs Limited (CONCORD) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹20.94 cr | ₹1.94 cr | ₹1.11 cr | 9.3% | 5.3% | ₹0.85 | +846.5% | +111.0% |
| Q4 FY262026-03-31 | ₹37.89 cr | ₹1.14 cr | ₹0.53 cr | 3.0% | 1.4% | ₹0.47 | — | +143.4% |
| Q3 FY262025-12-31 | ₹16.97 cr | ₹0.64 cr | ₹0.22 cr | 3.7% | 1.3% | ₹0.16 | — | +12.7% |
| Q2 FY262025-09-30 | ₹10.28 cr | ₹0.76 cr | ₹0.19 cr | 7.4% | 1.9% | ₹0.19 | — | +63.5% |
| Q1 FY262025-06-30 | ₹13.61 cr | ₹0.65 cr | ₹0.12 cr | 4.8% | 0.9% | ₹0.12 | — | — |
| TTM (last 4 quarters) | ₹86.07 cr | ₹4.48 cr | ₹2.05 cr | 5.2% | 2.4% | ₹1.67 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
CONCORD quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
Concord Drugs Limited quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹20.94 cr | ₹37.89 cr | ₹16.97 cr | ₹10.28 cr | ₹13.61 cr |
|---|
| Total expenses | ₹19 cr | ₹36.74 cr | ₹16.33 cr | ₹9.52 cr | ₹12.96 cr |
|---|
| Gross profit | ₹4.03 cr | ₹3.77 cr | ₹2.58 cr | ₹2.56 cr | ₹2.19 cr |
|---|
| Operating profit (EBIT) | ₹1.94 cr | ₹1.14 cr | ₹0.64 cr | ₹0.76 cr | ₹0.65 cr |
|---|
| Operating margin | 9.3% | 3.0% | 3.7% | 7.4% | 4.8% |
|---|
| Interest cost | ₹0.4 cr | ₹0.4 cr | ₹0.34 cr | ₹0.49 cr | ₹0.49 cr |
|---|
| Profit before tax | ₹1.54 cr | ₹0.75 cr | ₹0.3 cr | ₹0.27 cr | ₹0.16 cr |
|---|
| Tax expense | ₹0.43 cr | ₹0.22 cr | ₹0.08 cr | ₹0.08 cr | ₹0.04 cr |
|---|
| Effective tax rate | 27.9% | 29.4% | 26.7% | 29.1% | 25.7% |
|---|
| Net profit (PAT) | ₹1.11 cr | ₹0.53 cr | ₹0.22 cr | ₹0.19 cr | ₹0.12 cr |
|---|
| Net profit margin | 5.3% | 1.4% | 1.3% | 1.9% | 0.9% |
|---|
| Basic EPS | ₹0.85 | ₹0.47 | ₹0.16 | ₹0.19 | ₹0.12 |
|---|
| Diluted EPS | ₹0.85 | ₹0.47 | ₹0.16 | ₹0.19 | ₹0.12 |
|---|
CONCORD results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +53.9% | — | — | — | — |
|---|
| Revenue QoQ | -44.7% | +123.3% | +65.1% | -24.5% | — |
|---|
| Operating profit YoY | +199.3% | — | — | — | — |
|---|
| Operating profit QoQ | +69.8% | +79.8% | -16.2% | +17.1% | — |
|---|
| Net profit YoY | +846.5% | — | — | — | — |
|---|
| Net profit QoQ | +111.0% | +143.4% | +12.7% | +63.5% | — |
|---|
| EPS YoY | +608.3% | — | — | — | — |
|---|
| EPS QoQ | +80.9% | +193.7% | -15.8% | +58.3% | — |
|---|
CONCORD annual results history
Full-year performance for Concord Drugs Limited, useful for reading each quarter in context.
Concord Drugs Limited annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹78.74 cr | ₹45.24 cr | ₹44.92 cr | ₹52.08 cr |
|---|
| Total expenses | ₹75.55 cr | ₹42.53 cr | ₹42.39 cr | ₹49.04 cr |
|---|
| Gross profit | ₹11.09 cr | ₹10.01 cr | ₹11.67 cr | ₹11.08 cr |
|---|
| Operating profit (EBIT) | ₹3.19 cr | ₹2.72 cr | ₹2.54 cr | ₹3.04 cr |
|---|
| Operating margin | 4.0% | 6.0% | 5.6% | 5.8% |
|---|
| Interest cost | ₹1.71 cr | ₹2.03 cr | ₹1.87 cr | ₹1.73 cr |
|---|
| Profit before tax | ₹1.47 cr | ₹0.69 cr | ₹0.63 cr | ₹1.25 cr |
|---|
| Tax expense | ₹0.42 cr | ₹0.36 cr | ₹0.16 cr | ₹0.26 cr |
|---|
| Effective tax rate | 28.4% | 51.4% | 24.9% | 21.1% |
|---|
| Net profit (PAT) | ₹1.06 cr | ₹0.34 cr | ₹0.47 cr | ₹0.99 cr |
|---|
| Net profit margin | 1.3% | 0.7% | 1.1% | 1.9% |
|---|
| Basic EPS | ₹0.95 | ₹0.34 | ₹0.47 | ₹1.06 |
|---|
| Diluted EPS | ₹0.95 | ₹0.34 | ₹0.47 | ₹1.06 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹20.94 cr against ₹13.61 cr in Q1 FY26, and ₹37.89 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -44.7%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹19 cr, or 90.7% of revenue, with operating profit grew +199.3% year on year.
Margins, tax and profitability
Net profit of ₹1.11 cr works out to a net margin of 5.3% compared with 0.9% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, Concord Drugs Limited reported profit before tax of ₹1.54 cr, a tax charge of ₹0.43 cr (effective rate 27.9%), interest cost of ₹0.4 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹0.53 cr in Q4 FY26 to ₹1.11 cr in Q1 FY27, a change of +111.0%.
Trailing twelve months and annual context
Across the trailing four quarters Concord Drugs Limited has generated revenue of ₹86.07 cr and net profit of ₹2.05 cr, a trailing net margin of 2.4%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹78.74 cr with net profit of ₹1.06 cr and EPS of ₹0.95, versus the prior year where revenue grew +74.0% and profit grew +213.8%.
What to watch in the next CONCORD quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
Concord Drugs Limited has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
CONCORD results coverage
No results report published for CONCORD yet — our desk covers each quarter within minutes of the filing.
CONCORD quarterly results FAQs
What were Concord Drugs Limited (CONCORD) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), Concord Drugs Limited reported revenue of ₹20.94 cr and net profit of ₹1.11 cr, a change of +846.5% year on year on +53.9% revenue growth. EPS stood at ₹0.85.
What is CONCORD profit margin in Q1 FY27?
Concord Drugs Limited posted a net profit margin of 5.3% and an operating margin of 9.3% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹86.07 cr and net profit ₹2.05 cr.
Did CONCORD results beat the previous quarter?
Concord Drugs Limited net profit changed +111.0% quarter on quarter, from ₹0.53 cr in Q4 FY26 to ₹1.11 cr in Q1 FY27.
When are Concord Drugs Limited (CONCORD) quarterly results?
Concord Drugs Limited has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see CONCORD latest quarterly results?
Results coverage for CONCORD will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the CONCORD stock page.
What is Concord Drugs Limited annual revenue and profit?
For FY26, Concord Drugs Limited reported full-year revenue of ₹78.74 cr and net profit of ₹1.06 cr, with EPS of ₹0.95.
How many quarterly results has CONCORD declared recently?
Past results dates for CONCORD will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
